Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations

Louis P. Garrison, Ed Pezalla, Adrian Towse, Hongbo Yang, Elizabeth Faust, Eric Q. Wu, Nanxin Li, Eileen K. Sawyer, Michael Recht

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Gene therapy for hemophilia is designed to produce health gains for patients over many years. Rewarding that value creation on the basis of a one-time treatment implies a large upfront cost. This cost can only be justified by long-term health benefits and being cost-effective compared with conventional treatments. Yet, uncertainties about the long-term benefits make it challenging to assess clinical and economic value of gene therapies at launch. We identify and discuss key methodological challenges in assessing the value of gene therapy for hemophilia, including the immaturity of evidence on the durability of benefits, lack of definition and valuation of cure for chronic diseases, absence of randomized controlled trials, limitations of traditional quality of life measures in hemophilia, approach for qualifying cost-savings compared with current treatments, and choice of perspective. The Institute for Clinical and Economic Review has developed a framework for assessing single or short-term therapies (ICER-SST) and has applied it in hemophilia. After reviewing this framework and its application, we recommend the following when assessing the value of hemophilia gene therapies: (1) leveraging expert clinical opinion to justify assumptions on the durability of benefits; (2) using external synthetic controls and lead-in, self-controlled trials to assess comparative effectiveness; (3) addressing limitations of traditional quality of life measures through the use of modified utility collection approaches; (4) adjusting cost offsets from gene therapies with caution; (5) considering outcome-based contracting to address uncertainties about prices and long-term outcomes; and (6) presenting societal and healthcare system perspectives in parallel.

Original languageEnglish (US)
Pages (from-to)1628-1633
Number of pages6
JournalValue in Health
Issue number11
StatePublished - Nov 2021
Externally publishedYes


  • cost
  • gene therapy
  • hemophilia
  • valoctocogene roxaparvovec
  • value assessment

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations'. Together they form a unique fingerprint.

Cite this